Cedars-Sinai Medical Center
- Type
- Teaching hospital
- Where
- LOS ANGELES, CA
- Medicare CCN
- 050625
- Received
- $20,245,989 in 1,530 records, 2020 ($4,469,559 general, $15,776,429 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Cedars-Sinai Medical Center Fuzzy (name and state)
- Business registration: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Nonprofit contractor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying registrant: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: Cedars-Sinai Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 309 | $4,469,559 |
| 2020 | Research payment | 1,221 | $15,776,429 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,221 | $15,776,429 |
| Royalty or License | 11 | $2,587,021 |
| Grant | 68 | $835,239 |
| Education | 124 | $428,999 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 12 | $263,629 |
| Space rental or facility fees (teaching hospital only) | 56 | $145,994 |
| Consulting Fee | 9 | $91,724 |
| Charitable Contribution | 6 | $71,670 |
| Gift | 20 | $35,236 |
| Honoraria | 1 | $10,000 |
| Food and Beverage | 2 | $44 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Monteris Medical Corporation | $47,500 | Grant | In-kind items and services | Neuroblate Device, Neuroblate | 2020 | |
| 2020-12-31 | Merck Sharp & Dohme LLC | $39,083 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2020 |
| 2020-12-31 | Abbott Laboratories | $26,000 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | Intuitive Surgical, Inc. | $16,840 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Stryker Corporation | $12,932 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $11,433 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $8,863 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $8,017 | Education | In-kind items and services | CCU,MODULAR,IMAGE1 CONNECT,US Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $7,112 | Education | In-kind items and services | CCU,MODULAR,IMAGE1 CONNECT,US Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $7,086 | Research payment | In-kind items and services | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum Resistant Ovaria | 2020 | |
| 2020-12-31 | Brahms GmbH | $6,000 | Research payment | Cash or cash equivalent | BRAHMS KRYPTOR compact PLUS (instrument) Device, Kryptor instrument | Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto | 2020 |
| 2020-12-31 | Edwards Lifesciences Corporation | $5,215 | Research payment | Cash or cash equivalent | Early Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation (TMVI) System 2013-05C | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $4,918 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $4,409 | Education | In-kind items and services | CCU,MODULAR,IMAGE1 CONNECT,US Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | Linvatec Corporation | $3,976 | Grant | In-kind items and services | FLUID MANAGEMENT/PUMPS Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $3,809 | Education | In-kind items and services | CCU,MODULAR,IMAGE1 CONNECT,US Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $3,233 | Research payment | In-kind items and services | FASENRA Drug, Respiratory | A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study Of Benralizuma | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $3,172 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $3,123 | Education | In-kind items and services | POWER LED 175 LIGHT SOURCE W/SCB Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $2,681 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,397 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,332 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,108 | Education | In-kind items and services | CMOS VID. CHOLEDOCHOSCOPE 8.5 FR X 500MM Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $1,956 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $1,908 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,644 | Research payment | Cash or cash equivalent | CSMC2020MRIPR794IPR992Li | 2020 | |
| 2020-12-31 | Stryker Corporation | $1,540 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $1,521 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $1,357 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1,347 | Research payment | In-kind items and services | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $1,260 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,238 | Research payment | Cash or cash equivalent | CSMC2019MRIPR1101IPR1102IPR1103Maya | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,101 | Research payment | Cash or cash equivalent | CSMC2020MRIPR017Li | 2020 | |
| 2020-12-31 | Stryker Corporation | $1,020 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1,016 | Research payment | In-kind items and services | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $854 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | Abbott Laboratories | $750 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $750 | Research payment | Cash or cash equivalent | CSMC2019MRIPR785Xie | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $704 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $703 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $628 | Research payment | In-kind items and services | SPIES-H3-KT Device, VideoImaging | Efficacy of Near Infrared Incisionless Fluorescent Cholangiography (NIFC) During Laparoscopic Cholec | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $585 | Education | In-kind items and services | CCU,MODULAR,IMAGE1 CONNECT,US Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | Masimo Corporation | $585 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $510 | Education | In-kind items and services | CCU,MODULAR,IMAGE1 CONNECT,US Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $500 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | Abbott Laboratories | $495 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $481 | Education | In-kind items and services | CLAMPING JAW W/BALL JOINT, LRG 16.5-23MM Device, MICRO/NOTES/MILITARY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $481 | Education | In-kind items and services | CLAMPING JAW W/BALL JOINT, LRG 16.5-23MM Device, MICRO/NOTES/MILITARY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $443 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $360 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $352 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $333 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $260 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $259 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $236 | Research payment | In-kind items and services | C-MAC System Device, Airway | Evaluation of Utility of Bronchoscopy After Urgent Intubation | 2020 |
| 2020-12-31 | Masimo Corporation | $225 | Education | In-kind items and services | Patient SafetyNet System Device, Devices | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $163 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $163 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $162 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | KARL STORZ Endoscopy-America | $136 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $114 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $107 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | Masimo Corporation | $68 | Education | In-kind items and services | Patient SafetyNet System Device, Devices | 2020 | |
| 2020-12-31 | Masimo Corporation | $67 | Education | In-kind items and services | EMMA and ISA Device, Devices | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $61 | Education | In-kind items and services | CCU,MODULAR,IMAGE1 CONNECT,US Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $54 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $48 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $44 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $42 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $39 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $29 | Education | In-kind items and services | TELESCOPE,HOPKINS II, 30, 5mm x 29cm Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $24 | Education | In-kind items and services | HOLDING SYSTEM ROTATION SOCKET ONLY Device, LAPAROSCOPY | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $10 | Education | In-kind items and services | CCU,MODULAR,IMAGE1 CONNECT,US Device, VIDEOIMAGING | 2020 | |
| 2020-12-30 | Merck Sharp & Dohme LLC | $4,927 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-30 | Daiichi Sankyo Inc. | $891 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-12-29 | Karyopharm Therapeutics Inc. | $365 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | KCP-330-020 | 2020 |
| 2020-12-28 | BeiGene AUS Pty Ltd | $7,967 | Research payment | Cash or cash equivalent | A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics | 2020 | |
| 2020-12-28 | Merck Sharp & Dohme LLC | $805 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutatio | 2020 |
| 2020-12-24 | Merck Sharp & Dohme LLC | $4,614 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2020 |
| 2020-12-24 | PFIZER INC. | $47 | Research payment | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-12-23 | Edwards Lifesciences Corporation | $63,604 | Research payment | Cash or cash equivalent | EVOQUE TR 2019-06 | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $11,432 | Research payment | Cash or cash equivalent | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib | 2020 | |
| 2020-12-23 | Intercept Pharmaceuticals, Inc. | $11,418 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-12-23 | Edwards Lifesciences Corporation | $8,613 | Research payment | Cash or cash equivalent | The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study (2016-05) | 2020 | |
| 2020-12-23 | ABBVIE INC. | $5,355 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-066 | 2020 |
| 2020-12-23 | Spark Therapeutics, Inc. | $5,000 | Education | Cash or cash equivalent | 2020 | ||
| 2020-12-23 | Gilead Sciences, Inc. | $2,545 | Research payment | Cash or cash equivalent | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | 2020 | |
| 2020-12-23 | ABBVIE INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | 2020 | |
| 2020-12-23 | Edwards Lifesciences Corporation | $1,994 | Research payment | Cash or cash equivalent | CLASP IIF (2018-07) | 2020 | |
| 2020-12-23 | PFIZER INC. | $1,835 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $1,808 | Research payment | Cash or cash equivalent | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | 2020 | |
| 2020-12-23 | Edwards Lifesciences Corporation | $832 | Research payment | Cash or cash equivalent | Early Feasibility Study of the Edwards Tricuspid Transcatheter Repair System (2014-04) | 2020 | |
| 2020-12-22 | Genentech, Inc. | $6,368 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-12-22 | Smith+Nephew, Inc. | $5,920 | Gift | In-kind items and services | AMBIENT SUPER TURBOVAC Device, Sports Med Access | 2020 | |
| 2020-12-22 | Smith+Nephew, Inc. | $2,479 | Gift | In-kind items and services | HAT-TRICK Device, Extremities & Limb Restoration | 2020 | |
| 2020-12-21 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2020 |
| 2020-12-21 | Edwards Lifesciences Corporation | $7,002 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-12-21 | Janssen Research & Development, LLC | $2,498 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-21 | Boston Scientific Corporation | $2,438 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE III | 2020 |
| 2020-12-21 | BeiGene AUS Pty Ltd | $1,950 | Research payment | Cash or cash equivalent | A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics | 2020 | |
| 2020-12-18 | MERZ NORTH AMERICA, INC. | $30,000 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-18 | Janssen Research & Development, LLC | $580 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2020 | |
| 2020-12-17 | PFIZER INC. | $14,950 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EF | 2020 | |
| 2020-12-17 | Edwards Lifesciences Corporation | $7,186 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-12-17 | Eli Lilly and Company | $5,612 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATIO | 2020 | |
| 2020-12-17 | Merck Sharp & Dohme LLC | $5,368 | Research payment | In-kind items and services | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2020 |
| 2020-12-17 | E.R. Squibb & Sons, L.L.C. | $5,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-17 | Exelixis Inc. | $4,415 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | $2,140 | Research payment | Cash or cash equivalent | STUDY OF ASTX295 IN PATIENTS WITH SOLID TUMORS WITH WILD-TYPE P53 | 2020 | |
| 2020-12-17 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | 2020 | |
| 2020-12-17 | Roche Products Limited | $1,278 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2020 |
| 2020-12-17 | Roche Products Limited | $1,278 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2020 |
| 2020-12-17 | Genentech, Inc. | $800 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-12-17 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | MitraClip Device, Vascular | Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitr | 2020 |
| 2020-12-16 | Amgen Inc. | $157,797 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | EVENITY Biological, Bone Health | 2020 | |
| 2020-12-16 | Horizon Therapeutics plc | $62,500 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-16 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2020 |
| 2020-12-16 | Merck Sharp & Dohme LLC | $7,751 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2020 |
| 2020-12-16 | Intercept Pharmaceuticals, Inc. | $4,309 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-15 | Exelixis Inc. | $14,430 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Cook Incorporated | $5,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-15 | GlaxoSmithKline, LLC. | $1,881 | Research payment | Cash or cash equivalent | A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFF | 2020 | |
| 2020-12-15 | Exelixis Inc. | $1,137 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Brahms GmbH | $776 | Research payment | Cash or cash equivalent | BRAHMS KRYPTOR sFlt-1 and BRAHMS KRYPTOR compact PLUS consumables Device, Prenatal screening | Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto | 2020 |
| 2020-12-15 | Exelixis Inc. | $711 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Exelixis Inc. | $318 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Exelixis Inc. | $227 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Fisher Scientific Company L.L.C. | $15 | Research payment | In-kind items and services | sFlt-1 Device, prenatal screening | Identification and validation of a cut-off for the ratio of suluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto | 2020 |
| 2020-12-14 | E.R. Squibb & Sons, L.L.C. | $50,000 | Research payment | Cash or cash equivalent | Identification of Profibrotic Mechanisiums elaborated by KRT5+Basal Like cells in Idiopathic pulmunary fibrosis | 2020 | |
| 2020-12-14 | GlaxoSmithKline, LLC. | $9,160 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-12-14 | Alexion Pharmaceuticals, Inc. | $2,052 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-14 | Alexion Pharmaceuticals, Inc. | $1,316 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-14 | Alexion Pharmaceuticals, Inc. | $1,249 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-14 | Alexion Pharmaceuticals, Inc. | $989 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-14 | Medtronic USA, Inc. | $134 | Research payment | Cash or cash equivalent | INTERSTIM Device, Sacral Nerve Stimulation | ELITE | 2020 |
| 2020-12-11 | Medtronic USA, Inc. | $23,050 | Research payment | Cash or cash equivalent | INTERSTIM Device, Sacral Nerve Stimulation | ELITE | 2020 |
| 2020-12-11 | Allergan, Inc. | $2,000 | Education | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | 2020 | |
| 2020-12-11 | Bio-Rad Laboratories, Inc. | $641 | Gift | Cash or cash equivalent | Liquichek Device, Controls | 2020 | |
| 2020-12-10 | Edwards Lifesciences Corporation | $41,369 | Research payment | Cash or cash equivalent | ALTERRA Early Feasibility (2016-04) | 2020 | |
| 2020-12-10 | Alexion Pharmaceuticals, Inc. | $5,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | GlaxoSmithKline, LLC. | $4,225 | Research payment | Cash or cash equivalent | PHASE 1/2 CLINICAL STUDY OF NIRAPARIB IN COMBINATION WITH PEMBROLIZUMA | 2020 | |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $3,355 | Research payment | Cash or cash equivalent | AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYP | 2020 | |
| 2020-12-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ALUNBRIG Drug, ONCOLOGY | 2020 | |
| 2020-12-09 | Amgen Inc. | $29,477 | Research payment | Cash or cash equivalent | Validation of Zebra VCF Detection Algorithm | 2020 | |
| 2020-12-09 | United Therapeutics Corporation | $24,060 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | 2020 |
| 2020-12-09 | Novo Nordisk Inc | $23,228 | Research payment | Cash or cash equivalent | Victoza Biological, Diabetes | A phase II, randomized, double blind, placebo controlled trial of liraglutide in Parkinsons disease | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $20,550 | Research payment | Cash or cash equivalent | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2020 |
| 2020-12-09 | Horizon Therapeutics plc | $10,973 | Research payment | Cash or cash equivalent | TEPEZZA Drug, TEPEZZA | MULTICENTER, SAFETY AND EFFICACY, OPEN-LABEL EXTENSION STUDY EVALUATING TEPROTUMUMAB (HZN-001) TREATMENT IN SUBJECTS WIT | 2020 |
| 2020-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Abbott Laboratories | $1,572 | Research payment | Cash or cash equivalent | TriClip Transcatheter Tricuspid Valve Repair System Device, Cardiac Arrhythmias and Heart Failure | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2020 |
| 2020-12-08 | LEICA MICROSYSTEMS INC. | $200 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-12-07 | Boston Scientific Corporation | $76,395 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2020 |
| 2020-12-07 | Edwards Lifesciences Corporation | $10,150 | Research payment | Cash or cash equivalent | PARTNER II (2010-12) | 2020 | |
| 2020-12-07 | Edwards Lifesciences Corporation | $7,401 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2020 |
| 2020-12-07 | Boston Scientific Corporation | $2,690 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | PINNACLE FLX | 2020 |
| 2020-12-07 | BTG International Inc. | $1,000 | Grant | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | 2020 | |
| 2020-12-07 | Edwards Lifesciences Corporation | $787 | Research payment | Cash or cash equivalent | PARTNER II (2010-12) | 2020 | |
| 2020-12-07 | SANOFI US SERVICES INC. | $176 | Research payment | Cash or cash equivalent | SARCLISA Biological, Oncology | A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR6509 | 2020 |
| 2020-12-04 | Brahms GmbH | $250,000 | Research payment | Cash or cash equivalent | BRAHMS KRYPTOR sFlt-1 and PlGF Device, Prenatal screening | Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto | 2020 |
| 2020-12-04 | Merck Sharp & Dohme LLC | $101 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutatio | 2020 |
| 2020-12-03 | MEDIVATION LLC. | $35,754 | Research payment | In-kind items and services | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2020 |
| 2020-12-03 | Merck Sharp & Dohme LLC | $11,902 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-03 | Takeda Pharmaceuticals U.S.A., Inc. | $2,200 | Research payment | Cash or cash equivalent | ENTYVIO Biological, INTERNAL MEDICINE | LEVERAGING SOCIAL MEDIA FOR EDUCATING PATIENTS WITH INFLAMMATORY BOWEL DISEASE | 2020 |
| 2020-12-03 | Penumbra, Inc. | $195 | Research payment | Cash or cash equivalent | Indigo Device, Peripheral Intervention | CHEETAH | 2020 |
| 2020-12-02 | ABBVIE INC. | $9,500 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-066 | 2020 |
| 2020-12-02 | Arthrex, Inc. | $5,668 | Research payment | Cash or cash equivalent | DISTAL EXTREMITIES INSTRUMENTS FOOT & ANKLE DYNANITE Device, DISTAL EXTREMITIES | Coronal Versus Sagital Placementlof Staple in Capitolunate Fusion: A Biomechanical Study | 2020 |
| 2020-12-02 | ABBVIE INC. | $4,585 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-292 | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NINLARO Drug, ONCOLOGY | 2020 | |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | Arthrex, Inc. | $1,000 | Research payment | Cash or cash equivalent | SHOULDER INSTRUMENTS ELBOWS UCL Device, SHOULDER | Biomechanical Comparison of Ulnar Collateral Ligament Reconstruction with and without Internal Brace | 2020 |
| 2020-12-01 | Genentech USA, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | 2020 | |
| 2020-11-30 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,049 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Safety & Efficacy of Empa in patients with Acute HF | 2020 |
| 2020-11-29 | KARL STORZ Endoscopy-America | $337 | Education | In-kind items and services | HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY | 2020 | |
| 2020-11-27 | Eli Lilly and Company | $70,173 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-11-27 | Edwards Lifesciences Corporation | $5,642 | Research payment | Cash or cash equivalent | Trial #2017-18 ExCEED | 2020 | |
| 2020-11-25 | Abbott Laboratories | $13,650 | Research payment | Cash or cash equivalent | Portico Transcatheter Aortic HV Device, Cardiac Arrhythmias and Heart Failure | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO) | 2020 |
| 2020-11-25 | BeiGene AUS Pty Ltd | $5,920 | Research payment | Cash or cash equivalent | A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics | 2020 | |
| 2020-11-25 | Merck Sharp & Dohme LLC | $5,486 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $8,918 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2020 |
| 2020-11-24 | Bayer Healthcare Pharmaceuticals Inc. | $4,500 | Research payment | Cash or cash equivalent | Non-Covered | BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) | 2020 |
The latest 200 records of 1,530.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Los Angeles, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Los Angeles, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 3,857,263 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 3,898,747 | 10,014,009 | 39,538,223 |
| Median age B01002 | 37.2 | 38.2 | 37.9 |
| Under 18 B01001 | 19.2% | 20.6% | 22.0% |
| 65 and over B01001 | 14.2% | 15.2% | 15.7% |
| Households B11001 | 1,439,097 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 35.7% | 33.4% | 27.0% |
| Median household income B19013 | $81,939 | $90,112 | $99,122 |
| Median family income B19113 | $94,546 | $101,573 | $113,346 |
| Per capita income B19301 | $47,685 | $45,792 | $49,513 |
| Poverty rate B17001 | 16.5% | 13.7% | 12.0% |
| Unemployment rate B23025 | 8.2% | 7.3% | 6.6% |
| Civilian labor force B23025 | 2,128,918 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.7 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 38.5% | 36.0% | 37.1% |
| Housing units B25001 | 1,554,332 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 36.0% | 45.9% | 55.9% |
| Renters B25003 | 64.0% | 54.1% | 44.1% |
| Median home value B25077 | $921,200 | $834,200 | $734,700 |
| Median gross rent B25064 | $1,933 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 28.1% | 24.7% | 33.8% |
| Black B03002 | 8.1% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 47.2% | 48.4% | 40.2% |
| Asian B03002 | 11.9% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Los Angeles, CA.
Comments